RXRX
Recursion Pharmaceuticals, Inc.
7.34
USD
This page is just a preview of the data found in TrendSpider’s full version
Recursion Pharmaceuticals, Inc. stock is up 24.2% since 30 days ago. The next earnings date is Feb 26, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 5 PUTs, 5 CALLs. 50% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 15 Nov 16:29 | 15 Dec, 2023 | 10.00 | 1949 | ||
| 15 Nov 17:15 | 15 Dec, 2023 | 10.00 | 1949 | ||
| 16 Nov 14:30 | 15 Mar, 2024 | 7.50 | 1456 | ||
| 16 Nov 19:20 | 15 Dec, 2023 | 10.00 | 1913 | ||
| 17 Nov 16:01 | 15 Mar, 2024 | 10.00 | 368 | ||
| 21 Nov 20:51 | 15 Dec, 2023 | 6.00 | 513 | ||
| 22 Nov 14:31 | 15 Dec, 2023 | 6.00 | 921 | ||
| 27 Nov 16:06 | 15 Dec, 2023 | 10.00 | 1809 | ||
| 28 Nov 15:19 | 15 Dec, 2023 | 10.00 | 1809 | ||
| 01 Dec 18:35 | 17 Jan, 2025 | 10.00 | 57 |
Recursion Pharmaceuticals, Inc. engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation. REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer.
